Clinical Trial Update: Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety, reactogenicity, and effectiveness of Moderna's mRNA-1273.214 vaccine in infants was terminated, and trial results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Drugs mentioned

• mRNA-1273.214

Snippet

Sponsor: ModernaTX, Inc. | Conditions: SARS-CoV-2 | Phase 2 | Status: TERMINATED | Results posted: 2025-11-26